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Effect of IKZF1 deletions on signal 
transduction pathways in Philadelphia 
chromosome negative pediatric B-cell precursor 
acute lymphoblastic leukemia (BCP-ALL)
Naomi E van der Sligte1, Frank J G Scherpen1, Arja ter Elst1, Victor Guryev2, Frank N van Leeuwen3 
and Eveline S J M de Bont1*
Abstract 
Background: IKZF1 deletions are an unfavorable prognostic factor in children with Philadelphia chromosome posi-
tive (Ph+) as well as negative (Ph−) acute lymphoblastic leukemia (ALL). Although IKZF1 deletions occur in 10–15% 
of Ph− ALL cases, effects of IKZF1 deletions on signaling pathways in this group have not been extensively studied. 
Therefore, in this study we aimed to study the effect of IKZF1 deletions on active signal transduction pathways.
Methods: Multiplex ligation-dependent probe amplification (MLPA) was used to determine IKZF1 deletions and 
other copy number alterations in 109 pediatric B-Cell Precursor ALL (BCP-ALL) patients. Kinase activity profiling of 45 
primary Ph− BCP-ALL patients (31 IKZF1 wild type patients and 14 patients harboring an IKZF1 alteration) and western 
blot analysis of 14 pediatric BCP-ALL samples was performed to determine active signal transduction pathways.
Results: Unsupervised hierarchical cluster analysis of kinome profiles of 45 pediatric Ph− ALL cases showed no 
clustering based on IKZF1 status. Comparing the phosphorylation intensities of peptides associated with signaling 
pathways known to be involved in BCP-ALL maintenance, we did not observe differences between the two groups. 
Western blot analysis of 14 pediatric BCP-ALL samples showed large variations in phosphorylation levels between the 
different ALL samples, independent of IKZF1 status.
Conclusions: Based on these results we conclude that, although IKZF1 deletions appear to be an important clinical 
prognostic factor, we were unable to identify a unique IKZF1 dependent protein expression signature in pediatric Ph− 
ALL and consequently no specific targets for future therapy of Ph− IKZF1 deleted BCP-ALL could be identified.
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Background
Overall survival rates for children with Acute Lympho-
blastic Leukemia (ALL), the most common type of can-
cer in children, are approaching 90% [1]. Historically, risk 
stratification of newly diagnosed children was based on 
age and white blood cell count (WBC), but nowadays 
includes extensive cytogenetic and molecular analyses. 
In the past 5  years, genome wide approaches, studying 
DNA copy number alterations in ALL, have identified 
novel molecular markers that can be used for further 
risk stratification, including IKZF1 deletions as a predic-
tor of poor outcome. IKZF1 deletions can be identified 
in approximately 70% of the children with Philadelphia 
chromosome positive (Ph+) ALL and in 10–15% of the 
children with Philadelphia chromosome negative (Ph−) 
ALL and are associated with an increased relapse risk 
and decreased overall survival in both groups [2–4]. 
More recent studies indicate that the genomic context 
Open Access
*Correspondence:  E.S.J.M.de.Bont@umcg.nl 
1 Division of Pediatric Oncology/Hematology, Department of Pediatrics, 
Beatrix Children’s Hospital, University Medical Center Groningen, 
University of Groningen, PO Box 30.001, 9700 RB Groningen,  
The Netherlands
Full list of author information is available at the end of the article
Page 2 of 10van der Sligte et al. Exp Hematol Oncol  (2015) 4:23 
in which IKZF1 deletions occur is more important for 
prognosis as for example CRLF2 and JAK2 mutations 
are more common in IKZF1 deleted BCP-ALL [5–7]. In 
pediatric B-cell progenitor ALL (BCP-ALL), 80% of the 
IKZF1 deletions are found in a Philadelphia chromosome 
negative background.
IKZF1, which encodes the transcription factor Ikaros, 
is essential for normal lymphoid development, whereas 
for erythroid and myeloid lineage differentiation IKZF1 
is less critical [8]. Mice deficient for IKZF1 show a com-
plete arrest in B-lymphocyte development while mice 
heterozygous for a dominant-negative mutation of IKZF1 
develop T cell leukemia and lymphoma with a 100% 
penetrance [9, 10]. During normal development, Ikaros 
restricts the G1-S transition of the cell cycle when it binds 
to the DNA, by regulating transcription of cell cycle reg-
ulator genes e.g. a positive effect on cell cycle inhibitors 
CDKN1A (p21Cip1) and CDKN1B (p27Kip1) [11]. Phos-
phorylation of Ikaros by casein kinase II (CK2) temporar-
ily reduces Ikaros binding to DNA and thereby facilitates 
progression through the S phase of the cell cycle [11]. 
Furthermore, Ikaros can be phosphorylated by spleen 
tyrosine kinase (SYK) and bruton’s tyrosine kinase (BTK) 
[12, 13]. These phosphorylation events are essential for 
nuclear localization, regulation of DNA binding activity, 
and an optimal transcriptional function of Ikaros [12, 13].
IKZF1 deletions observed in BCP-ALL are typically 
mono-allelic, either resulting in a loss of function or 
the expression of a dominant-negative isoform [14]. 
The dominant-negative isoforms lack the DNA binding 
N-terminal zinc fingers, preventing DNA binding after 
dimerization with Ikaros [15]. As a result, the control 
of Ikaros on the G1-S transition is abolished leading to 
hyperproliferation and the development of leukemia [11].
Although the cure rates for children with BCP-ALL 
have improved substantially, the outcome after ALL 
relapse remains poor. Since IKZF1 deletions increase 
the risk of relapse, new therapeutic options aiming to 
improve cure rates for this specific subtype of ALL are 
needed. We have previously shown that insight into 
active signal transduction pathways allows identifica-
tion of interesting targets for future therapy [16–19]. At 
the level of signal transduction, Iacobucci et  al. showed 
on western blot analysis a higher STAT5 phosphoryla-
tion in IKZF1 deleted compared to IKZF1 wild type adult 
BCP-ALL patients with unknown cytogenetic back-
ground [20]. However, this observation might also be 
associated with BCR-ABL1 activity as in adult BCP-ALL 
patients IKZF1 deletions are more common in Ph+ ALL 
[21]. Additionally, Ikaros-reconstitution in two IKZF1 
deleted Philadelphia positive ALL patients resulted in an 
upregulation of the B-cell receptor (BCR) signaling path-
way and a concomitant cell cycle arrest; showing that in 
Ph+ ALL pre-B cell receptor signaling suppresses prolif-
eration through an Ikaros-mediated cell cycle arrest [22]. 
Although IKZF1 deletions in children are most com-
monly found in a Philadelphia negative background, the 
effect of IKZF1 deletions on signaling pathways in Phila-
delphia negative ALL have not been extensively studied. 
Therefore, in this study we aimed to study the effect of 
IKZF1 deletions on active signal transduction path-




Primary blood and bone marrow samples from newly 
diagnosed ALL patients were collected after getting writ-
ten informed consent in accordance with the regulations 
and protocols of the medical ethics committee of the 
University Medical Center Groningen. Overall, we col-
lected material of 109 Philadelphia negative BCP-ALL 
patients. Mononuclear cells were isolated by Lympho-
prep (Nycomed, Zürich, Switzerland) density gradients 
and cryopreserved in liquid nitrogen until use. The cry-
opreserved leukemia cells were thawed rapidly at 37°C 
and diluted in a 6 ml volume of newborn calf serum, as 
described earlier [23].
DNA isolation
Genomic DNA was extracted from mononuclear cells 
using the QIAamp DNA easy kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. All 
isolated DNA was quantified by NanoDrop spectropho-
tometry (NanoDrop, Wilmington, DE, USA).
Multiplex ligation‑dependent probe amplification (MLPA)
Targeted copy number screening of eight selected loci was 
performed in the cohort by multiplex ligation-dependent 
probe amplification (MLPA) using the P335-B2 SALSA 
MLPA kit (MRC-Holland, Amsterdam, The Netherlands). 
The assay includes probes for each of the eight exons of the 
IKZF1 gene and is able to detect deletions of the whole gene 
as well as all types of focal intragenic deletions. Selected 
exons of the genes BTG1, CDKN2A/B, EBF1, ETV6, PAX5, 
RB1 and the PAR1 region (approx. 230 kbp downstream 
of SHOX, CRLF2, CSF2RA and IL3RA) are also covered. 
Probe mix and hybridization buffer (MRC-Holland) were 
added in equal amounts to 50  ng of genomic DNA fol-
lowed by heat denaturation and overnight hybridization of 
the probes at 60°C. Subsequently, ligation was performed 
and the ligation products were amplified by PCR using a 
6-FAM fluorophore-labeled primer set (MRC-Holland). 
The amplification products were quantified and identified 
by capillary electrophoresis on an ABI 3730 DNA analyzer 
(Applied Biosystems, Foster City, CA, USA).
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Data analysis: Data were analyzed using Gene Mapper 
v.4.0 software (Applied Biosystems). Normalization of 
the data was carried out by dividing the peak area of each 
probe by the average peak area of the control probes. 
This normalized peak pattern was divided by the average 
peak pattern of all the samples in the same experiment. 
The resulting values were 1 for every wild-type peak, 
0.5 for heterozygous deletions and 1.5 for heterozygous 
duplications.
PepChip
Kinase activity profiles of 45 primary Ph− BCP-ALL 
patients were determined using the PepChip™ Kinom-
ics microarray system (Pepscan, Lelystad, the Nether-
lands) and performed as described previously [18, 19]. 
The microarray contain 1,024 peptides in triplicate (1,008 
unique target peptides and 16 peptides used for produc-
tion) derived from known phosphorylation sites from 
human protein sequences that can be phosphorylated 
by the kinases in the sample lysate. Per sample, 0.5 × 106 
cells were lysed in 100 μl of M-PER Mammalian Protein 
Extraction Buffer containing 1 μl Phosphatase Inhibitor 
and 1 μl Protease Inhibitor (Pierce, Rockford, IL, United 
States). Peptide array incubation mix was produced by 
adding 10 μl of filter-cleared activation mix onto 90 μl 
cell lysate. Peptide array incubation mix was loaded on 
the chip and incubated for 2 h at 37°C in a closed humid 
box at saturated humidity. Subsequently, the peptide 
array was washed and blow dried with compressed air 
or N2 and the chips were exposed to a phospho-storage 
screen for 24–96  h. The amount of bound 33P-labelled 
ATP to the peptides specifies the amount of peptide 
phosphorylation and was analyzed with array software 
(ScanAlyze, Eisen Lab, University of California at Berkely, 
Berkely, CA, United States).
Data analysis: Data were analyzed as described previ-
ously [18, 19]. In short, background was subtracted and 
the spot intensities were quantile normalized. A Pearson’s 
correlation coefficient was determined over the triplicates 
(Excel 2003, Microsoft Office, Redmond, WA, United 
States). Slides with a correlation <0.6 over the triplicates 
were excluded from further analysis. The correlation over 
the triplicates was <0.6 in none of the samples. Cluster, 
statistical and heatmap analysis were performed using 
Qlucore Omics Explorer 3.0 (Qlucor AB, Lund, Sweden). 
The file containing the processed raw data can be found 
in the additional information (Additional file 1: Table S1).
Western blot analysis
Primary ALL cells were solved in laemmli sample 
buffer (Bio-Rad laboratories, Veenendaal, the Neth-
erlands). Proteins were separated by sodium dode-
cyl sulphate–polyacrylamide gel electrophoresis, and 
transported to nitrocellulose membranes. Membranes 
were blocked in 7.5% skimmed milk and incubated 
overnight with primary antibodies for phospho-Src_
Y416, phospho-Syk_Y323, phospho-ERK1/2_T202/
Y204, phospho-CREB_S133, phospho-p38_T180/
Y182, phospho-Akt_S473, phospho-mTOR_S2448, 
phospho-GSK3α/β_S21/S9, phospho-MDM2_S166, 
phospho-Chk2_T68, phospho-RB1_S807/811, phospho-
STAT3_Y705, phospho-STAT5_Y694 (Cell Signaling, 
Danvers, MA, USA), or phospho-p27_T187 (Abgent, San 
Diego, CA, United States) and for 1 h with HRP conju-
gated secondary antibodies (Dako, Glosturp, Denmark). 
Protein bands were visualized using the  ChemiDoc  MP 
imaging system (Bio-Rad, Hercules, CA, United States) 
and  ImageLab  software (version 5.0,  Bio-Rad Laborato-
ries). Loading control was visualized using β-actin (Santa 
Cruz Biotechnology, Dallas, TX, United States).
Results
Generation of kinase activity profiles in IKZF1 deleted 
versus IKZF1 wild type Philadelphia negative pediatric 
BCP‑ALL
MLPA analysis revealed that among the 109 Philadel-
phia negative pediatric BCP-ALL patients tested, 17 
(15.6%) patients harbor an IKZF1 deletion whereas one 
patient (0.9%) showed a gain of IKZF1. We generated 
kinase activity profiles of 31 IKZF1 wild type patients and 
14 patients with an IKZF1 alteration (13 patients with 
an IKZF1 deletion and 1 patient with a gain of IKZF1). 
No material was available for kinome profiling of the 
other three patients with an IKZF1 deletion. Among 
the 14 patients harboring an IKZF1 alteration, deletions 
in exons 1 through 8 (4 patients, 28.6%), 4 through 7 (3 
patients, 21.4%), and 4 through 8 (3 patients, 21.4%) were 
most frequent (Fig. 1). Patients’ characteristics are shown 
in Fig. 1. Patients harboring an IKZF1 alteration appeared 
to be older compared to IKZF1 wild type patients (8.4 
versus 5.7  years, respectively, P  =  0.038). Furthermore, 
MLPA analysis showed more CSF2RA alterations in the 
group with IKZF1 alterations compared to the IKZF1 
wild type group (P = 0.003).
Kinase activity profiles were generated to reveal poten-
tial differences in signaling between IKZF1 deleted and 
non-deleted Ph− pediatric BCP-ALL cases. Compared to 
previously performed kinome arrays, we observed a good 
variability in peptide phosphorylation intensities among 
the 1,008 unique target peptides and within the 45 indi-
vidual patients, indicating that the experimental condi-
tions were optimal. Unsupervised hierarchical cluster 
analysis showed no clustering based upon IKZF1 status 
(Fig.  2a). Moreover, no differential clustering could be 
observed based on karyotype and copy number altera-
tions of PAX5, ETV6, CDKN2A, CDKN2B, and CRLF2 
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(Fig. 2a). The clustering in peptide activity was not corre-
lated to patients’ characteristics as age, gender, and white 
blood cell count (WBC) at diagnosis (Additional file  2: 
Figure  S1). To evaluate whether IKZF1 deletions display 
a unique kinase signature we studied differences in pep-
tide phosphorylation intensities by t-test analysis. Thirty-
eight peptides were differentially phosphorylated between 
IKZF1 deleted (N =  13) and IKZF1 wild type (N =  31) 
pediatric Ph− BCP-ALL patients: phosphorylation of 14 
peptides was higher in the IKZF1 deleted group and 24 
peptides showed reduced phosphorylation intensities 
(P ≤ 0.05, Fig. 2b, Additional file 3: Table S2). In Fig. 2b, 
normalized peptide intensities are shown with each vari-
able normalized to mean 0 and variance 1. Although 
we observed thirty-eight peptides to be differentially 
phosphorylated, absolute differences of normalized pep-
tide phosphorylation intensities between IKZF1 deleted 
and wild type samples were small (Additional file  4: 
Figure  S2; Additional file  3: Table  S2). Focusing on the 
normalized peptide phosphorylation intensities, high 
phosphorylation levels of peptides derived from Cyto-
hesin-1_S394 and Cytohesin-2_S392 were shown. The 
list of top 100 most highly phosphorylated peptides also 
showed only subtle variations between IKZF1 deleted and 
wild type cases (Additional file 5: Table S3). Although no 
gross differences in peptide phosphorylation levels were 
observed, the list of top 100 highest phosphorylated pep-
tides included a number of potentially druggable targets 
for the treatment of BCP-ALL. Among the top 100 most 
highly phosphorylated peptides, we identified 86 peptides 
Fig. 1 Patients’ characteristics. Clinical and genetic characteristics as well as copy number alterations identified using multiplex ligation-dependent 
probe amplification (MLPA) analysis are shown for 45 patients who were included in the kinome analysis.
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Fig. 2 Kinome profile in Philadelphia chromosome negative pediatric BCP-ALL patients. a Unsupervised hierarchical clustering of 45 pediatric 
BCP-ALL cases; 13 IKZF1 deleted, 1 IKZF1 gain, and 31 IKZF1 wild type Philadelphia chromosome negative patients based on 1,008 unique target 
peptides. No distinct clustering could be observed based on IKZF1 status, neither on genetic background or other copy number alterations. b 
Unsupervised hierarchical clustering of 44 pediatric BCP-ALL cases; 13 IKZF1 deleted and 31 IKZF1 wild type patients based on 38 differentially 
phosphorylated peptides identified by t test. Each row represents a peptide, each column represents a single ALL sample. The magnitude of devia-
tion from the median is represented by the color saturation with each variable normalized to mean 0 and variance 1. Red and green spots display the 
phosphorylation intensity above and below the median, respectively.
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previously defined as activated peptides in pediatric ALL 
including cAMP responsive element binding protein 1 
(CREB1), peptides derived from protein kinases related 
to the PI3K/Akt-signaling pathway including peptides 
related to phosphatidylinositol 3 kinases and ribosomal S6 
kinases, and peptides derived from regulators of the cell 
cycle including checkpoint kinase 2 and retinoblastoma 1 
[19].
Signal transduction pathway activation in response 
to IKZF1 status
To focus more closely on active signal transduction 
pathways, we determined peptide phosphorylation 
of proteins involved in important signaling pathways 
for BCP-ALL cell proliferation and survival (e.g. the 
BCR signaling pathway, the MAPK, PI3K/Akt/mTOR, 
JAK/STAT5 signaling pathways), adhesion pathways, 
and regulators of the cell cycle (including p21Cip1 
and p27Kip1, Fig. 3). Activity of these signaling path-
ways could be observed in both IKZF1 wild type and 
IKZF1 deleted pediatric Ph− ALL patients. Compar-
ing phosphorylation intensities of peptides associ-
ated with these main signaling pathways showed no 
differences in pathway activation between IKZF1 wild 
type and IKZF1 deleted Ph− ALL (Additional file  6: 
Table S4).
Fig. 3 Signal transduction in IKZF1 deleted versus wild type cases in Philadelphia chromosome negative pediatric BCP-ALL patients. Shown are 
peptide phosphorylation intensities of proteins involved in important signal transduction pathways for BCP-ALL cell proliferation and survival. 
Results are expressed in gray scale representing the mean peptide phosphorylation intensity of all category peptides.
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Phosphorylation levels of key signaling proteins in IKZF1 
deleted and wild type BCP‑ALL
Previously, upregulation of the B-cell receptor (BCR) 
signaling pathway was reported in adult Ph+ ALL in 
response to Ikaros-reconstitution, as well as an increased 
STAT5 phosphorylation in IKZF1 deleted versus wild 
type adult ALL cases with unknown cytogenetic back-
ground [20, 22]. Although various peptides involved in 
the BCR signaling pathway and peptides derived from 
STAT5 were present on the array, we did not observe 
these differences in our Ph− cases. Therefore, in addition 
to the kinome profiles, we performed western blot analy-
sis of 14 pediatric BCP-ALL samples; seven Philadel-
phia negative IKZF1 wild type patients, six Philadelphia 
negative IKZF1 deleted patients, and one Philadelphia 
positive IKZF1 deleted patient (Fig. 4). The western blot 
results showed a large variation in phosphorylation lev-
els between the different ALL samples. STAT5_Y694 
phosphorylation could be detected in the Philadelphia 
positive patient (patient no 14) and in two Philadelphia 
negative patients with an IKZF1 deletion (patients no 6 
and 8), but was not detectable in the other IKZF1 deleted 
Philadelphia negative patients (patients no 7, 9, 10, and 
13, Fig. 4). The western blot results showed that protein 
phosphorylation of Src_Y416, Syk_Y323, ERK1/2_T202/
Y204, CREB_S133, p38_T180/Y182, Akt_S473, mTOR_
S2448, GSK3α/β_S21/S9, MDM2_S166, p27_T187, 
Chk2_T68, Rb1_S807/811, and STAT3_Y705 was clearly 
independent of IKZF1 status. Neither did we observe 
a clear relation between the western blot results and 
known copy number alterations of PAX5, ETV6, Rb1, 
CDKN2A, CDKN2B, or CRLF2 (Fig.  4). In conclusion, 
our kinome and western blot results suggest that IKZF1 
deletions do not predict a unique protein expression sig-
nature in pediatric Ph− ALL.
Discussion
IKZF1 deletions are found in approximately 70% of 
the children with Philadelphia chromosome positive 
(Ph+) ALL and in 10–15% of the children with Philadel-
phia chromosome negative (Ph−) ALL. In both groups, 
IKZF1 deletions are associated with an increased risk 
on relapse and decreased overall survival [2–4]. In Ph− 
ALL, the effect of IKZF1 deletions on outcome is most 
pronounced in children with an intermediate treatment 
response based on the minimal residual disease at days 42 
and 84 [24]. Although multiple studies have established 
IKZF1 as a prognostic factor in pediatric BCP-ALL, the 
effect of IKZF1 deletions on signaling pathways in Phila-
delphia negative B-cell precursor ALL is poorly under-
stood. In previous studies, we have shown that kinome 
profiling can be used successfully to describe active signal 
transduction pathways in pediatric malignancies [16–19]. 
In this study we used kinome profiling to elucidate the 
effect of IKZF1 deletions on active signal transduction 
pathways.
Unexpectedly, unsupervised hierarchical cluster analy-
sis revealed no clustering between IKZF1 deleted and 
wild type patients. Furthermore, peptide phosphoryla-
tion intensities between IKZF1 deleted and wild type Ph− 
BCP-ALL patients were very comparable as shown by the 
phosphorylation intensities of the thirty-eight differen-
tially phosphorylated peptides and by the list of top 100 
most highly phosphorylated peptides. While focusing on 
important signaling pathways involved in cell prolifera-
tion and survival of BCP-ALL cells we showed activity of 
all these pathways, however, no differences between the 
IKZF1 deleted versus the IKZF1 wild type group could be 
observed. Moreover, western blots of several key proteins 
involved in ALL signaling showed a variety of phospho-
rylation events, clearly unrelated to IKZF1 status.
Although no clear differences in peptide phospho-
rylation intensities could be observed, kinome profiles 
showed a remarkable high phosphorylation of peptides 
derived from Cytohesin-1_S394 and Cytohesin-2_S392. 
Cytohesins have been described as ErbB receptor acti-
vators [25]. It has been described that Cytohesin over-
expression enhances epidermal growth factor receptor 
(EGFR) signaling in human cancers including lung cancer 
and colorectal cancer [25, 26]. Although kinase domain 
mutations of ErbB receptors are uncommon in acute leu-
kemias, in vitro inhibition of ErbB2 reduces cell prolifera-
tion especially when combined with BCR-ABL tyrosine 
kinase inhibitors in Ph+ ALL, suggesting a role for ErbB 
signaling pathway activation in leukemia [27, 28]. There-
fore, it will be interesting to further explore the role of 
Cytohesin in BCP-ALL.
Although we did not identify a unique kinome signa-
ture as a result of IKZF1 status, effects of IKZF1 deletions 
on gene expression were described previously. Iacobucci 
et al. showed that IKZF1 deletions display a unique gene 
expression signature in a cohort of adult B-ALL patients, 
including patients with a Philadelphia translocation and 
B-ALL patients negative for known molecular rearrange-
ments [20]. The gene expression signature was charac-
terized by the downregulation of genes regulating B-cell 
lineage development and DNA repair upon DNA damage 
response genes and upregulation of cell cycle/apoptosis 
genes, JAK/STAT signaling and stem cell self-renewal 
[20]. More recently, besides an upregulation of genes 
associated with B-cell proliferation, an upregulation of 
genes involved in cell adhesion and communication was 
also observed in pediatric Ph− ALL [29].
In addition to a unique IKZF1 dependent gene 
expression profile, a subtype of precursor BCP-ALL 
with a similar gene expression profile compared to 
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Philadelphia-positive ALL was identified several years 
ago (Ph-like ALL) [2, 30]. Importantly, 68% of the patients 
with Ph-like ALL showed deletions in IKZF1 [31]. Within 
the Ph-like ALL subtype, 5-year event-free survival rates 
in patients with IKZF1 alterations were inferior compared 
to Ph-like IKZF1 wild type ALL patients [31]. Recently, 
Roberts et  al. defined the genomic landscape of Ph-like 
ALL in a large cohort of children and adolescents to elu-
cidate kinase-activating genetic alterations which might 
include potential leads for targeted therapy [31]. Genomic 
alterations activating kinase signaling were identified 
in 91% of the Ph-like ALL patients (N =  156) including 
ABL-class fusions, rearrangements of JAK2 or CRLF2, 
genetic alterations including IL7R and FLT3, and Ras 
pathway mutations [31]. Patients harboring IKZF1 altera-
tions (N = 96, 61.5%) were distributed over all groups of 
different kinase alterations, indicating a high degree of 
heterogeneity within the group of IKZF1 deleted patients 
[31]. Our results and the results of Roberts et al. suggest 
that patients harboring IKZF1 alterations represent a 
Fig. 4 Protein phosphorylation profiles in Philadelphia chromosome negative pediatric BCP-ALL patients. Western blot analysis of 14 pediatric 
BCP-ALL samples; seven Philadelphia negative IKZF1 wild type, six Philadelphia negative IKZF1 deleted patients, and one Philadelphia positive IKZF1 
deleted patient showing phosphorylation expression levels of a selection of proteins. The results show a great diversity in phosphorylation levels 
between the different ALL samples independently of IKZF1 status and other copy number alterations.
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heterogeneous subgroup when evaluated at the level of 
active signal transduction pathways. The identification of 
potential targets for tyrosine kinase inhibitors therefore 
appears to be dictated by upstream genomic alterations 
that activate kinase signaling or cytokine receptor path-
ways rather than IKZF1 status per se.
Conclusions
The aim of this study was to elucidate the effect of IKZF1 
deletions on active signal transduction pathways using 
kinome profiling and western blot analysis in children 
with Ph− BCP-ALL. Although IKZF1 deletions are an 
important clinical prognostic factor we were unable to 
identify a unique IKZF1 associated protein expression 
signature in pediatric Ph− BCP-ALL and consequently no 
specific targets for future therapy of Ph− IKZF1 deleted 
BCP-ALL were identified.
Abbreviations
ALL: acute lymphoblastic leukemia; BCP-ALL: B-cell progenitor acute  
lymphoblastic leukemia; BCR: B-cell receptor; BTK: Bruton’s tyrosine kinase; 
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between IKZF1 deleted (N = 13) and IKZF1 wild type (N = 31) Philadelphia 
negative pediatric BCP-ALL patients as determined by t-test analysis. The 
phosphorylation of 14 peptides was higher in the IKZF1 deleted group 
and 24 peptides showed reduced phosphorylation intensities. Shown are 
the normalized peptide phosphorylation intensities as well as P values.
Additional file 4: Figure S2. Absolute phosphorylation intensities of 38 
differentially phosphorylated peptides. Supervised hierarchical clustering 
of 44 pediatric BCP-ALL cases; 13 IKZF1 deleted and 31 IKZF1 wild type 
Philadelphia chromosome negative patients based on 38 peptides identi-
fied by t-test. Each row represents a peptide, each column represents a 
single ALL sample. Absolute phosphorylation intensities are shown by the 
color saturation, red and green spots display high and low phosphoryla-
tion intensities, respectively.
Additional file 5: Table S3. Top 100 most highly phosphorylated 
peptides. Shown is the list of top 100 highest phosphorylated peptides in 
IKZF1 deleted and IKZF1 wild type Philadelphia negative pediatric BCP-ALL 
patients. Highlighted peptides are overlapping peptides between IKZF1 
deleted and IKZF1 wild type.
Additional file 6: Table S4. List of proteins involved in important 
signaling pathways for BCP-ALL. Shown are proteins involved in important 
signaling pathways for BCP-ALL cell proliferation and survival (e.g. the 
BCR signaling pathway, the MAPK, PI3 K/Akt/mTOR, JAK/STAT5 signaling 
pathways), adhesion pathways, and regulators of the cell cycle (including 
p21Cip1 and p27Kip1). The mean normalized phosphorylation intensities 
of multiple peptides derived from indicated proteins as well as P-values 
are shown for IKZF1 deleted (N = 13) and IKZF1 wild type (N = 31) pediat-
ric patients.
CK2: casein kinase II; MLPA: multiplex ligation-dependent probe amplification; 
Ph−: Philadelphia chromosome negative; Ph+: Philadelphia chromosome posi-
tive; SYK: spleen tyrosine kinase.
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